Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514159 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL224335 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6514157 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL224337 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6278265 | 1.00 | DDB1 (0.38) | DDB1CRBNCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6522689 | 0.93 | — | — | |
| SCHEMBL4211980 | 0.93 | — | — | |
| SCHEMBL6513927 | 0.93 | — | — | |
| SCHEMBL6522687 | 0.93 | — | — | |
| SCHEMBL6513930 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | disclosed |
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3038621-B1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RES INSTITUTE (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | disclosed |
| US-9045423-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8791090-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20130172345-A1 | 1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | KOWA COMPANY, LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050228016-A1 | TETRAHYDROQUINOLINES FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | MICHELOTTI ENRIQUE | 2005-10-13 | — | — | US | disclosed |
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1513530-A1 | TETRAHYDROQUINOLINES FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003105849-A1 | TETRAHYDROQUINOLINES FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | DDB1 1670/4885CRBN 4452/4885CHRNB2 2332/4885 |
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | DDB1 1925/4885CRBN 4589/4885CHRNB2 2766/4885 |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | DDB1 2927/4885CRBN 3794/4885CHRNB2 4841/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | DDB1 3363/4885CRBN 3771/4885CHRNB2 1564/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | DDB1 3486/4885CRBN 3436/4885CHRNB2 1372/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | DDB1 1925/4885CRBN 4589/4885CHRNB2 2766/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | DDB1 3124/4885CRBN 3985/4885CHRNB2 1514/4885 |
| US-20050228016-A1 | TETRAHYDROQUINOLINES FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, GTF2E2, NR2C2 | DDB1 67/4885CRBN 3259/4885CHRNB2 715/4885 |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | DDB1 1592/4885CRBN 4075/4885CHRNB2 2067/4885 |
| US-20130172345-A1 | 1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | EPOR, HBG2, HBG1 | DDB1 3502/4885CRBN 3352/4885CHRNB2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.